8–12 Week Results With Kligman Formula: Evidence and Risks
The Kligman formula is a prescription triple-combination cream that pairs a bleaching agent, a retinoid and a corticosteroid to treat melasma, post-inflammatory hyperpigmentation and solar lentigines. It is compounded to a clinician’s specification, never sold over the counter, and requires monitoring for skin thinning and irritation.
TL;DR:
- The Kligman formula’s effectiveness relies on precise percentages of hydroquinone, tretinoin, and corticosteroids, with higher hydroquinone doses increasing ochronosis risk.
- Short-term skin clearance for melasma is well-supported, but long-term superiority over other treatments remains unproven, especially in darker skin types.
- Common side effects include skin irritation, which usually subsides, but prolonged corticosteroid use risks skin thinning and telangiectasia, requiring short courses and monitoring.
- Application must be done carefully: apply a thin layer after thorough drying, wait 30 minutes before bed, and use daily sunscreen to maintain results.
- Repeated or indefinite use of the full-strength formula is discouraged; non-steroidal alternatives and procedural options are recommended for long-term maintenance.
Table of Contents
- What is the Kligman formula made of?
- How does the Kligman formula actually work?
- Does the evidence support using it for melasma?
- What side effects and risks should you watch for?
- How is it prescribed and applied correctly?
- What are the alternatives and long-term maintenance options?
- Why we take a cautious, individualised approach to prescribing it
- Get clinician-led pigmentation treatment through Them-ethod
- Sources
What is the Kligman formula made of?
Albert Kligman and colleagues published the original formula in 1975, combining tretinoin, hydroquinone and the corticosteroid dexamethasone in specific concentrations in a single base. That paper, Kligman’s original depigmentation study, found that complete depigmentation only occurred when all three actives worked together. None achieved the same result alone.
Modern practice has moved away from those exact figures. The best-known commercial version, Tri-Luma, contains fluocinolone acetonide 0.01%, hydroquinone 4% and tretinoin 0.05%, according to its official product monograph on DailyMed. Compounding pharmacies produce further variations tailored to skin type, tolerance and pigmentation severity. Some compounded listings show hydroquinone at 6% paired with hydrocortisone 0.5% and tretinoin 0.025%, a milder steroid at a higher bleaching dose.
This variability is the point, not a flaw. A clinician adjusts the ratio for darker skin tones, sensitive skin or a patient who has already tried hydroquinone treatment for hyperpigmentation without success. When you’re assessing a preparation, check for:
- The exact percentage of hydroquinone, since anything above 4% carries a higher ochronosis risk with prolonged use
- The retinoid strength, usually tretinoin between 0.025% and 0.1%
- The corticosteroid class and potency, which determines how long you can safely use the cream
- The base (ointment versus cream), which affects absorption and how it feels on the skin
- Storage instructions, since these creams typically need refrigeration or protection from light to remain stable
How does the Kligman formula actually work?
Each ingredient does a distinct job, and none of them substitutes for the others.
- Hydroquinone inhibits tyrosinase, the enzyme melanocytes need to produce melanin, which slows new pigment formation rather than stripping out existing colour instantly.
- Tretinoin speeds up epidermal turnover, shedding pigmented skin cells faster and helping the other two ingredients penetrate more effectively.
- The corticosteroid calms the irritation that hydroquinone and tretinoin cause on their own, and may contribute a modest depigmenting effect of its own.
That three-way division of labour is why the combination often outperforms hydroquinone or a retinoid used alone. The retinoid opens the door, the hydroquinone does the main pigment-blocking work, and the steroid stops the whole regimen from becoming intolerable.
Pro Tip: If a single-agent brightening serum has stalled your progress after several months, that plateau is often exactly what triple therapy is designed to break through, because it attacks pigment production and skin turnover at the same time.
Does the evidence support using it for melasma?
Kligman’s 1975 paper remains the founding reference. It reported that combining all three actives, not anyone or two, produced complete depigmentation in his study population. That single finding shaped melasma treatment for the following five decades.
More recent research complicates the picture usefully. A 2025 systematic review and meta-analysis confirmed that triple-combination therapy reduces melasma severity in the short term, typically measured using the Modified Melasma Area and Severity Index (mMASI). But the same review found no statistically significant advantage over comparator treatments during the maintenance phase, and the pooled studies showed high heterogeneity in design, population and duration.
What the numbers actually show: short-term clearing is well documented and reproducible across trials, but long-term superiority over other approaches is not.
That distinction matters for anyone weighing up realistic expectations. Broader literature searchable through PubMed includes multiple randomised trials and comparative studies, but few follow patients for more than a few months, and study populations vary enormously by skin type and baseline pigmentation severity. Practical takeaways worth holding onto:
- Expect visible improvement in mMASI scores within 8 to 12 weeks for most responders
- Relapse after stopping treatment is common, which is why maintenance planning matters as much as the initial course
- Darker skin types (Fitzpatrick IV to VI) are underrepresented in many of the older trials, so individual results can vary from published averages
What side effects and risks should you watch for?
Local irritation is the most frequent complaint, and it is largely predictable. Redness, peeling, burning, dryness and itching are common in the first two to four weeks, according to Cleveland Clinic’s guidance on the combined cream. These usually settle as the skin adjusts, and applying a thinner layer or reducing frequency to alternate nights often resolves them without stopping treatment entirely.
The corticosteroid component carries the more serious longer-term risk. Extended use can cause skin thinning, visible thread veins (telangiectasia) and steroid-induced dermatitis or rosacea-like eruptions, particularly on the face where skin is thinner than elsewhere on the body. That is precisely why triple therapy is prescribed in short courses rather than as an indefinite daily routine.
Hydroquinone brings its own distinct concern: exogenous ochronosis, a paradoxical blue-black discolouration that can occur with prolonged or excessive use, especially at higher concentrations. It is uncommon at the doses used in supervised short courses, but it is one reason self-sourced, unsupervised hydroquinone products carry real risk.
Follow these steps to reduce harm:
- Apply only the amount your clinician specifies, never more, even if results feel slow.
- Stop and contact your clinician if you notice unusual darkening, persistent burning, or thinning skin.
- Book a review appointment at the interval your clinician sets, typically every 6 to 8 weeks.
- Seek urgent care for signs of infection, severe blistering, or an allergic reaction.
How is it prescribed and applied correctly?
Because the Kligman formula is compounded, quality and consistency depend entirely on the prescribing clinician and the pharmacy filling the order. This is not a formula to self-mix or source from unregulated sellers. A proper assessment considers your Fitzpatrick skin type, pigmentation history, and any prior steroid sensitivity before settling on a strength.
Application technique matters as much as the formula itself. Cleveland Clinic and Mayo Clinic both instruct patients to apply a thin, almost invisible layer to clean, dry skin at least 30 minutes before bedtime, never more often or more heavily than prescribed.
- Wash and thoroughly dry the treatment area before application.
- Use a pea-sized amount for the entire face, spreading it thinly rather than dabbing it on thickly.
- Wait the full 30 minutes before lying down to avoid transferring product to bedding or eyes.
- Apply broad-spectrum sunscreen every morning without exception, following a daily Korean skincare routine, since UV exposure can undo weeks of progress.
Pro Tip: If you can still see a white or shiny residue on your skin ten minutes after applying, you’ve used too much. Wipe off the excess and use less next time. More product does not mean faster results, only more irritation.
Courses typically run for a matter of weeks to a few months, after which most clinicians transition patients to non-steroidal maintenance to avoid cumulative steroid exposure. A melasma skincare routine built around daily photoprotection is what keeps results from fading once the active course ends.
What are the alternatives and long-term maintenance options?
Modified Kligman formulas, using lower steroid potency or reduced hydroquinone percentages, exist specifically to soften the trade-off between speed and safety for patients who need repeated courses over years rather than months.
Once a course ends, non-steroidal maintenance takes over. Azelaic acid, topical tranexamic acid, and gentler retinoids can hold pigment in check without the steroid-related risks of long-term use. Procedural options such as certain peels or laser treatments, explored in depth through protocols like BRIGHT SKY for pigmentation and melasma, offer another route for patients who prefer to avoid repeated topical steroid exposure altogether.
- Favour a non-steroidal alternative if you have a history of steroid intolerance or rosacea.
- Discuss alternatives with your clinician if you are pregnant or planning pregnancy, since hydroquinone and tretinoin are not recommended in that context.
- Expect individual variation: some alternatives perform comparably in trials, but response depends heavily on your skin type and pigmentation depth.
Why we take a cautious, individualised approach to prescribing it
The gap between what triple-combination therapy promises and what it reliably delivers is where most patients get misled. Marketing around “the Kligman formula” often implies a fixed, universally effective recipe. In practice, the 1975 concentrations, the Tri-Luma monograph strengths, and the compounded variants we see in clinic are three different things, and treating them as interchangeable is where problems start.
Our clinicians select concentrations based on Fitzpatrick type, prior steroid exposure and pigmentation depth, then review progress at set intervals rather than leaving patients on an open-ended course. That individualisation, not the formula itself, is what separates a good outcome from a frustrating one. If you’re considering this treatment, a proper skin consultation before you start is worth more than any percentage printed on a label.
— Jess
Get clinician-led pigmentation treatment through Them-ethod
Them-ethod exists precisely for readers who’ve reached this point and want prescription-strength answers rather than another over-the-counter serum that promises the same result without the mechanism to back it up. Our virtual skin consultations connect you with clinicians who assess your pigmentation, skin type and history before recommending a course, whether that means a compounded triple-combination cream or a maintenance protocol using products from our NEOSTRATA collection once your active treatment ends. As a UK-based Obagi Ambassador Clinic, we handle the prescribing and monitoring that this category genuinely requires, rather than leaving you to guess at concentrations alone. If persistent melasma or post-inflammatory marks have resisted your current routine, book a virtual consultation with Them-ethod and get a plan built around your skin, not a generic percentage.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
Sources
- Fluocinolone; Hydroquinone; Tretinoin skin cream — Cleveland Clinic
- Efficacy and safety of Kligman’s formula in the treatment of melasma: a systematic review and meta analysis — Archives of Dermatological Research
- A new formula for depigmenting human skin — Kligman 1975 (Arch Dermatol)
- Tri-Luma — DailyMed
- Fluocinolone; hydroquinone; tretinoin topical — Mayo Clinic
